Research Reports Coverage on Biotech Stocks -- Merrimack Pharma, Aurinia Pharma, Aegerion Pharma, and TG Therapeutics

NEW YORK, October 24, 2016 /PRNewswire/ -- has on its radar four these Biotech equities, namely: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and TG Therapeutics Inc. (NASDAQ: TGTX). According to IBISWorld's global market research report dated May 2016, industry value added (IVA) of the segment is expected to grow 3.5% per year on average during the ten years to 2021, slightly greater than annualized global GDP growth of 2.7% over the same period. These stocks research reports can be downloaded now by simply registering for free at:

Merrimack Pharma  

Massachusetts headquartered Merrimack Pharmaceuticals Inc.'s shares jumped 8.20%, finishing last Friday's session at $5.54. A total volume of 8.13 million shares was traded, which was above their three months average volume of 2.78 million shares. Over the previous three months, the stock has advanced 0.54%. The Company's shares are trading above their 50-day moving average by 7.13%. Additionally, shares of Merrimack Pharma, which engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have a Relative Strength Index (RSI) of 54.47.

On October 7th, 2016, research firm JP Morgan downgraded the Company's stock rating from 'Overweight' to 'Neutral'.

On October 11th, 2016, Merrimack Pharmaceuticals announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin.  The extended data cutoff occurred at final database lock in November 2015 after 382 OS events that had occurred in the intention-to-treat (ITT) population. In this extended analysis of NAPOLI-1, the previously described overall survival advantage was maintained for ONIVYDE in combination with 5-FU and leucovorin versus 5-FU and leucovorin alone: 6.2 months versus 4.2 months. Findings also showed that one in four patients treated with the ONIVYDE combination regimen survived one year or more, a significant milestone. Your complete research report on MACK can be retrieved for free at:

Aurinia Pharma  

On Friday, shares in Canada headquartered Aurinia Pharmaceuticals Inc. ended the session 3.92% lower at $3.68. The stock recorded a trading volume of 1.34 million shares. The Company's shares have surged 61.19% in the last month, 21.45% over the previous three months, and 48.99% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 30.38% and 34.74%, respectively. Moreover, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have an RSI of 53.22.

On October 6th, 2016, Aurinia announced 24-week data in all 10 patients from the AURION study, an open-label exploratory study to assess the short-term predictors of response using voclosporin in combination with mycophenolate mofetil (MMF) and oral corticosteroids in patients with active lupus nephritis (LN). In this study, 70% patients achieved complete remission at 24 weeks as measured by a urinary protein creatinine ratio (UPCR) of ≤ 0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of <5mg/day. AUPH free report is just a click away at:

Aegerion Pharma  

Massachusetts headquartered Aegerion Pharmaceuticals Inc.'s stock gained 0.91%, to close the day at $2.21 with a total trading volume of 180,729 shares. The Company's shares have advanced 50.34% in the previous three months. The stock is trading 8.23% above its 50-day moving average. Additionally, shares of Aegerion Pharma, which develops and commercializes therapies for patients with debilitating rare diseases in the US, have an RSI of 47.15.

On September 28th, 2016, Aegerion announced that Japan's Ministry of Health, Labor & Welfare has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).  HoFH is a serious, rare genetic disease that impairs the function of the receptor responsible for removing LDL-C ("bad" cholesterol) from the body. Sign up for your complimentary research report on AEGR at:

TG Therapeutics  

Shares in TG Therapeutics Inc. recorded a trading volume of 693,774 shares, which was above their three months average volume of 433,760 shares. The stock ended Friday's session at $6.41, up 5.78%. The Company's shares have gained 10.71% in the previous three months. The stock is trading below its 50-day moving average by 8.50%. Furthermore, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 40.94.

On October 6th, 2016, research firm Brean Capital resumed its 'Buy' rating on the Company's stock, issuing a target price of $28 per share.

On October 20th, 2016, TG announced the launch of a Phase 1/2 study to evaluate the safety and efficacy of TGR-1202, its oral PI3K delta inhibitor in combination with carfilzomib, the FDA-approved proteasome inhibitor, in patients with relapsed or refractory lymphoma. Register for free on and download the latest research report on TGTX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.